Pierandrea Muglia

Over more than two decades, Dr. Muglia has led the development of large and small molecules for numerous neurology and psychiatric indications for Parkinson’s and Huntington disease, epilepsy, schizophrenia, depression, bipolar disorders and neuro-orphan indications.
Possessing a unique blend of business and R&D experience, Dr. Muglia has held numerous leadership and entrepreneurial roles across large - (GSK) and medium-size (UCB) pharma and biotech. Most recently Dr. Muglia served as Vice President and head of neurology early clinical development at UCB Pharma, where he contributed to shape the neurology strategy and pipeline organically and inorganically through assets and company acquisitions, he served as CMO at Handl Therapeutics and was President and Founder of GRIN Therapeutics, a clinical stage company, for which he raised the capital necessary to develop a small molecule for a genetically defined orphan epilepsy syndrome.

Dr Muglia has advisory roles in a number of biotech companies developing novel therapeutics for CNS disorders. He is Board member of Saniona AB, a Scandinavian public company active in developing new treatments for CNS indications.

During his tenure as Academic Clinicians, before his pharma career, Dr. Muglia served Residence roles at the Child Psychiatry Services, in the Dept. of Public Health, San Francisco (1996), he was Post-doc MRC-Canada Fellow and then Scientist at the Centre for Addiction and Mental Health, and Assistant Professor at the Department of Psychiatry, University of Toronto (1998-2002). Dr Muglia has over 100 publications in the field of neuropsychopharmacology, drug development, and human genetics in high impact journals and he is part of scientific advisory board and committees of not-for-profit initiatives and orphan disease patient advocacy associations.